A genome-wide association study described the potential roles of insulin and obesity-related factors on RCC risk.
Concerns about conflict of interest as it relates to prescribing may never go away, some say, as long as drug companies offer doctors money for consulting and personal services.
In a Canadian matched cohort study, intolerance drove patients with CP-CML to switch from generic imatinib at a higher frequency compared with those given brand-name products.
In a statement announcing a newly created partnership, the Botanical Safety Consortium, FDA Commissioner Scott Gottlieb made no mention of cannabidiol.
New studies in glioblastoma highlight how PD-1 inhibitors could simultaneously prompt an immune response and steer the selection of tumor clones that evade immune recognition.
At 23 years of follow-up, the cumulative incidence of death was higher among patients in the watchful waiting group compared with those in the radical prostatectomy group.
"People have shown that the variant-identification quality of WGS is superior to WES," said Dr Gerstein.
Researchers identified 15 genes that they said independently predict the survival outcome of patients with kidney renal papillary cell carcinoma.
Patient-reported outcomes, or PROs, are going to play a larger role in FDA cancer drug approvals, according to an expert in the field.
The objective of this initiative was to identify gaps in oncology clinicians' knowledge, competence, and performance with respect to treatment of geriatric patients with cancer, whether in an academic medical center or community setting.
Articles discussing the use of cannabis as a substitute for opioids highlight the limitations of the existing scientific evidence in the field.
The continuous decline in cancer deaths over the past 25 years was attributed to improvements in screening, treatment.
Experts examined the role of population-based early detection cancer screening.
Researchers are excited about the prospect to use vaccines in combination with checkpoint inhibitors to improve the body's cancer-fighting ability.
Inhibition of ER translocation prevented both ERK reactivation and autophagy, suggesting a potential strategy for improving BRAF and MEK inhibition therapy outcomes.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Immunotherapy in Glioblastoma: Peaks and Pits
- Opinion: Understanding the FDA's Take on Cannabidiol
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Polymorphism in HSD3B1 as a Potential Prognostic Biomarker in Prostate Cancer
- Opioid Use and Cancer
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk